Vigil Neuroscience, Inc. (NASDAQ:VIGL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.60.

Several analysts have issued reports on VIGL shares. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a research note on Friday, November 8th. William Blair initiated coverage on Vigil Neuroscience in a research report on Wednesday. They issued an “outperform” rating on the stock. Guggenheim reduced their price target on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, Wedbush boosted their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in Vigil Neuroscience during the second quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the second quarter worth $87,000. Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares in the last quarter. Walleye Capital LLC lifted its holdings in shares of Vigil Neuroscience by 334.4% during the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after buying an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Vigil Neuroscience during the third quarter worth $442,000. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Stock Down 2.9 %

Shares of NASDAQ:VIGL opened at $2.33 on Wednesday. The firm has a market cap of $95.25 million, a price-to-earnings ratio of -1.13 and a beta of 1.65. Vigil Neuroscience has a 12 month low of $2.08 and a 12 month high of $6.06. The company’s fifty day simple moving average is $3.37 and its 200 day simple moving average is $3.62.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.